Institutional Ownership
Galectin Therapeutics Inc
CUSIP 363225202COM NEWGALTQ1 2026
13D / 13G Filings
0
Schedule 13D/13G on record
Beneficial Filers
0
Distinct reporting persons
Largest Stake
—
Max % of class reported
Institutional Holders
95
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
Schedule 13D (activist) & 13G (passive) 5%+ ownership filings
No 13D/13G filings on record yet
Schedule 13D/13G beneficial-ownership filings from 2020–present are ingested from SEC EDGAR. Coverage expands as the backfill and daily crawler run.
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Marshall Wace, LLP | 1.22M | $3.40M |
| 2 | Osaic Holdings, Inc. | 1.12M | $3.13M |
| 3 | Blackrock, Inc. | 799.2K | $2.23M |
| 4 | Millennium Management LLC | 798.4K | $2.23M |
| 5 | Wealthspire Advisors, LLC | 721.8K | $2.01M |
| 6 | Geode Capital Management, LLC | 612.8K | $1.71M |
| 7 | Susquehanna International Group, LLP | 555.7K | $1.55M |
| 8 | Two Sigma Investments, LP | 467.1K | $1.30M |
| 9 | Commonwealth Equity Services, LLC | 367.1K | $1.02M |
| 10 | Citadel Advisors LLC | 290.4K | $810.1K |